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Abstract 
Background: The scientific community has proven the value of circulating tumor cells 
(CTCs) as a prognostic factor in the development of cancer and progress to metastases 
[1–4]. Simultaneously, a new type of cancer stem cell-like (CSC-like) cells has also been 
established as a progenitor of metastases and relapses in cancer patients [5, 6]. The 
present research attempts to support the hypothesis that CTCs have all the cellular 
hallmarks of CSC-like cells which play a crucial role in cancer spreading.  
Materials and Methods: Two methods have been chosen: a cellular-based and a 
molecular-based method. The first method is based on the fact that CSCs form 
microspheres in culture. In the second method, microspheres develop in the presence of 
specific markers that define the CSC phenotype [6].  
Results: In cellular-based assays, it has been shown that microspheres form in semi-
suspension in a culture flask. In the second panel of the test, Nanog was chosen as a 
marker and the tested sample was positive when grown under specific conditions.  
Conclusion: Our analysis has demonstrated that in this particular case, CSCs-like cells are 
included in the vast majority of CTCs. 
 
Introduction 
It is well known that circulating tumor cells (CTCs) are a distinct population of cancer 
cells that have detached from the primary tumor and flow into the blood circulation, 
creating a secondary tumor. Their role in the metastatic pathway has proven to be 
essential [4, 9–12]. 
Initiation of metastasis involves CTCs creation which includes cell-to-cell adhesion 
mechanisms and cell mobility. Several growth factors act in order to stimulate the 
epithelial-to-mesenchymal transition (EMT). The primary epithelial cancer cells interact  
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with the basement membrane via multiple biochemical changes and acquire a 
mesenchymal cell phenotype. Through the blood vessels, they migrate into distant healthy 
tissues. Their survival depends on the interaction between them and the host. As this 
biological process progresses, during the cancer cells’ extravasation many angiogenic 
factors and signaling agents contribute to the colonization. Accordingly, through 
mesenchymal-to-epithelial transition (MET) – the opposite of EMT – a micrometastasis 
occurs followed by a macrometastasis [10, 11, 13–15]. 
Thus, CTCs can be considered as the progenitors of relapses. This indicates that they 
may have all the hallmarks of cancer stem cell-like (CSC-like) cells, as CSCs have the 
ability to give rise to a new tumor [5, 16]. This assumption needs to be confirmed in a 
case report or extended analysis. 
Materials and Methods 
To provide more accurate evidence for the existence of CSC-like cells within CTCs in the primary 
tumor, it was necessary to use more than one approach: the first method was cellular-based and the 
second one was molecular-based.  
CTC Isolation 
To isolate CTCs, whole blood cells were centrifuged with polysucrose solution [Histopaque 1077 
(10771; Sigma) layered on Histopaque 1119 (11191; Sigma)]. Mononuclear cells, lymphocytes, platelets, 
and granulocytes were collected after centrifugation and washed twice with PBS. Cells were then 
incubated at 4°C for 30 min with EpCAM magnetic beads (39-EPC-50; Gentaur). EpCAM is an 
epithelial cell adhesion molecule-associated antigen that is expressed in the vast majority of carcinomas. 
As breast cancer is of epithelial origin, EpCAM beads were used for breast cancer CTC isolation. 
Following incubation, the sample was placed in a magnetic field, selected and washed with PBS. Isolated 
breast cancer cells were then divided and cultured in a 25-cm
2 flask (5520100; Orange Scientific) with 
RPMI-1640 medium (R6504; Sigma). Since the cancer cells have an infinite division potential, the cells 
that remained in the flask after 1 week of culture were the cells of preference [4, 17]. 
Blood Sample Collection 
Cancer cells were obtained from a 55-year-old female patient with breast cancer stage II (lobular 
invasive ductal carcinoma, grade 2). Thereafter, 20 ml of peripheral blood was collected from the patient 
and placed in a tube with EDTA as anticoagulant (Vacutainer K3E; BD) and rotated for 30 min to 
prevent coagulation. 
Flow Cytometry 
To determine the presence of breast cancer cells in our sample, flow cytometry was performed as 
method of choice. Briefly, 10 μl of CD45-PC5 (MCA1719C; AbD Serotec) and 10 μl of CD31-PE 
(MCA1738PE; AbD Serotec) antibodies were added to 100 μl of whole blood. In a second tube, 10 μl of 
CD45-PC5 and 10 μl of c-Met (FAB3582P; RnD Systems) antibodies were added to 100 μl of whole 
blood. Both of the above samples were prepared twice, followed by incubation for 25 min at room 
temperature. After incubation, 100 μl of medium A (Leucoperm, BUF09; AbD Serotec), containing 
formaldehyde (0.1% v/v), was added to each of the 4 sample tubes. The samples were then washed with 
3 ml of PBS (P3813; Sigma) containing 5% w/v FBS (10106–169; Invitrogen) and 0.1% v/v NaN3 (S8032; 
Sigma) and centrifuged for 5 min at 1,600 rpm. Supernatant was removed and 100 μl of medium B 
(Leucoperm) was added to each tube. To the first couple of tubes (CD31 and c-Met), containing 
intracellular pan-cytokeratin (ABIN144814; GeneTex), antibody was added. To the second couple of 
tubes, CD227 (MCA1742F; AbD Serotec) was added. Samples were incubated for 25 min at room  
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temperature. After a second wash, the samples were analyzed by Accuri C6 cytometer (Accuri C6; 
Accuri). 
Cell Culture 
As positive control, we used Human Breast Cancer Stem Cell Culture (36102–29-T25; Celprogen) 
which has been provided by Celprogen. Both CTCs and Human Breast Cancer Stem Cell Culture were 
incubated in 25-cm
2 flasks (5520100; Orange Scientific) at 37°C in 5% CO2 atmosphere. As culture 
medium for the Human Breast Cancer Stem cell culture, the STEMPRO hESC SFM kit was used 
(A10007–01; Invitrogen) which stimulates the growth of human mammary epithelial cells and provides 
the highest quality for microsphere culture. The STEMPRO product (complete medium) is composed of 
a DMEM/F-12 + GlutaMAX (1X) cultivation medium and by the following additional ingredients: 10 
μg/ml of FGF-basic factor (F029; Sigma), STEMPRO hESC SFM Growth Supplement (50X), 25% of 
BSA, and 55 mmol/l of 2-mercaptoethanol (M3148; Sigma). CTCs were cultivated both in RPMI-1640 
(R0883; Sigma), with the appropriate amount of heat-inactivated fetal bovine serum (10106-169, FBS; 
Invitrogen), and 2 mmol/l glutamine (G5792; Sigma), and in the STEMPRO kit in order to make a 
comparison under different conditions from the starting population. All the experiments were done 
during the exponential phase and after a culture confluence of 80–90%.  
Cellular-Based Evaluation Method 
This method is based on the ability of CSCs to form microspheres. To analyze the microsphere-
positive population, after 48 h of cultivation, we compared the capacity of RPMI-1640-cultivated cells 
and STEMPRO-cultivated cells based on their ability to form spherical colonies in semi-suspension 
using the Human Breast Cancer Stem Cell Culture as positive control. Light microscope was used for 
assessment and evaluation. 
Molecular-Based Evaluation Method 
This scientific approach is based on the fact that the CSC phenotype is defined by multiple molecular 
markers such as Nanog, oct4, nestin, E-cadherin, AML1, ALDH, etc. For gene expression analysis, 
endpoint and quantitative RT-PCR protocols have been used (Maxima Sybr Green K0221; Fermentas), 
and flow cytometry analysis has been used for protein expression (Accuri C6; Accuri) [7, 8, 18–20]. 
Gene Expression Analysis 
The primers used in the endpoint RT-PCR protocol were designed by the Genamics expression 
program (Genamics Expression, version 1.100
© 2000). The endpoint RT-PCR protocol used to test the 
gene expression of interest includes a 10-min template initial denaturing step at 95°C, a 45-second main 
denaturing step at 94°C, a 45-second primer annealing step at 59°C, and a 2-min primer extension step 
at 72°C. Usually, a 10-min final extension step is performed and the reaction runs for 45 cycles to obtain 
gene patterns (Nanog gene: forward: 5c-TGAGATGCCTCACACGGAGACTG-3c, reverse: 5c-
GGGTTGTTTGCCTTTGGGACTG-3c). 
Protein Expression Analysis 
The quantitative evaluation of Nanog protein-expressing cells has been performed using a murine 
antihuman antibody conjugated with fluorescein isothiocyanate, a major fluorescein derivative 
(ABIN278021; Antibodies-online GmbH), and by the FCS express software (FCS Express V3, version 
3.00.0504, Professional Standalone, 2001–2007; DeNovo Software).  
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Results 
The outcome of the cellular-based assays has pointed out the formation of 
microspheres in semi-suspension inside a culture flask [9]. As mentioned before, CSC-
like cells have the ability to form spherical colonies under enabling conditions. To analyze 
this type of formation in our cultures, we compared RPMI-1640-cultivated cells and 
STEMPRO-cultivated cells with the formation of human breast CSCs (control cell line) 
(fig. 1). 
In the second panel of the test, the representative marker (Nanog gene) of choice [5, 
21, 22] was found to be positive in the human breast CSC sample, as expected. 
STEMPRO-cultivated cells were also found to be positive, in contrast to RPMI-cultivated 
cells, where an expression of the Nanog gene was missing (fig. 2). 
In order to check the protein expression of Nanog, flow cytometry analysis has been 
used. The cells shown in fig. 3 and in fig. 4 represent the percentage of RPMI-1640-
cultivated cells, which expressed 1.24% of Nanog protein, and the percentage of 
STEMPRO-cultivated cells, which expressed 4.79% of Nanog protein of the total amount. 
Consequently, Nanog protein has been observed to be highly expressed in STEMPRO-
cultivated cells. 
Using all the evaluating methods described above, we tested the expression of Nanog 
from transcription to translation in order to draw the final conclusions.  
Discussion 
The most striking or crucial characteristic of cancer disease is its ability to spread and 
produce new metastatic sites. In alignment with the scientific indications cited above, 
CTCs, which are part of the primary tumor, play an important role for the development 
of the disease, and later, of metastasis [15, 16, 23–25]. 
Shortly, a tumor is formed when cancer cells grow as colonies. Many cellular and 
biochemical changes in the phenotype are responsible for the loss of epithelial hallmarks 
by the tumor cells. 
Loss of epithelial polarity (interaction between tumor cells and stromal cells) drives 
CTCs to alter themselves and form spheres. This shape facilitates their immune escape, 
and finally reacts with the target. Ras/MAPK pathway is activated and EMT takes place. 
Expression levels of epithelial markers like E-cadherin and cytokeratin decrease and, as a 
result, the linkage between CTCs and actin cytoskeleton is weakened. In contrast, many 
mesenchymal markers, such as vimentin and fibronectin, are expressed in high levels and 
so cancer cells (CTCs) acquire a fibroblast-like shape and their mobility and invasiveness 
increases. As a result, circulation of tumor cells via proliferation through the blood 
circulation (intravasation) is taking place. CFS-1 and EGF are the major stimulators of 
this process, as well as a great range of metalloproteinases (MMPs), especially MMP-9 
and G proteins (e.g., Ras, Rho). MMP-9 expression correlates with the 
tumorigenesis/metastasis cascade. It is well known that metalloproteinase plays a crucial 
role in normal tissues, as it is initially synthesized as soluble inactive pro-enzyme and acts 
like a caspase. Other caspases act then in order to stimulate the metastatic attitude of 
MMPs. On the contrary, G proteins like Ras and Rho are members of a signal  
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transduction pathway, and their activation causes cell growth, differentiation and 
survival. Thus, using blood vessels, CTCs flow and reach the targeted place, where they 
are released via extravasation and produce new tumors (micrometastases). Since the 
environment lacks the previously owned signals and growth factors, CTCs need time in 
order to proliferate and find all necessary growth supplements to finally produce the 
detectable mass (macrometastasis) [10, 11, 14, 17]. 
Many efforts have been done by others in order to prove that cells which have detached 
from the primary tumor are CTCs [17, 24–26]. However, these methods present 
advantages and disadvantages. The first one is a PCR-based method which does not 
sustain cells as entity for analysis, meaning that there are limitations concerning further 
molecular analysis of CTCs. Furthermore, even if we have the ability to enumerate CTCs 
[4], we have identified only few molecular characteristics. The second widely used method 
is a magnetic bead-based method which uses a small range of markers in order to enrich 
the CTC population; hence, it is based on their positive selection [17]. 
In this research attempt, more than one method has been used to render the results 
more accurate and complete. CTCs isolation from the patient’s blood sample was made 
using EpCAM magnetic beads, which is a pan-epithelial carcinoma-associated antigen 
that is expressed in almost all carcinomas, as mentioned before. Following isolation, 
CD45-negative selection was performed in order to isolate cells of epithelial origin from 
the remaining blood cells. Moreover, CD31-positive cells, endothelial cells or pericytes 
were excluded because they were considered normal. 
The MET gene encodes protein that triggers tumor proliferation, neovascularization 
and metastases to distinct organs. Therefore, c-Met-positive cells are cells of interest. 
Expression of cytokeratins is organ and tissue specific. Moreover, the cytokeratin profile 
tends to remain intact when an epithelial cell undergoes a malignant transformation. 
Therefore, a cytokeratin profile study is helpful for tumor characterization [4, 24, 25]. 
The CD227 (Mucin-1 or Ca 15.3) antigen is highly expressed by virtually all mucosal 
epithelial tissues. It is aberrantly expressed in most human breast cancers, and in this 
study it was used as a breast cancer marker. CTCs were quantified in the sample [3, 27, 
28]. 
The hypothesis that a population of CTCs has many CSC-like hallmarks is reinforced 
by the expression of related molecular markers. NANOG is a transcription factor which 
plays an important role in the self-renewal of undifferentiated embryonic stem cells. It is a 
nuclear protein and its function is correlated with other factors such as OCT4 [POU5F1 
(POU class 5 homeobox 1)]. It has been shown that these genes play a key role in forming 
the identity of embryonic stem cells. Oct4 is initially active in the oocyte, and it remains 
active even later in the preimplantation period. It forms a dimmer with the Sox2 gene and 
so binds to the DNA. Studies claim that this dimmer activates the Nanog protein, and so 
this molecular cascade is responsible for the capability of tumor cells to differentiate into 
any of the 3 germ layers (pluripotency). Another protein that expresses early during cell 
development is Nestin. It is a marker that is not expressed in adults because it is replaced 
by tissue-specific intermediate filament proteins. Due to the above-mentioned reasons, 
these markers were chosen in order to prove the initial hypothesis. Since CSCs must hold 
the hallmark of self-renewal and asymmetric cell division, which is driven by the above 
factors, the present attempt shows that this hallmark also exists in CTCs [7, 19, 29, 30].  
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Conclusion 
Our analysis has well pointed out that in this particular case, CSC-like cells are 
included in the vast majority of CTCs. It is also hypothesized that this model could be 
applied in general for all cancer metastasis processes. Furthermore, it is necessary to 
perform further extended studies in different types of malignancies and in a larger scale of 
sample types in order to prove the relevance between CTCs and CSCs. 
 
 
 
 
 
 
Fig. 1. Human breast CSCs. 
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Fig. 2. The CSC-like cell phenotype is associated with the expression of the Nanog gene [7]. Here, its 
expression was determined by RT-endpoint PCR. The predicted size of the PCR product was 104 bp. 
The Nanog gene was highly expressed in both CSC-like cells (A, B) and in one of the two samples of 
STEMPRO-cultivated cells (C, D). In samples E and F (RPMI-1640-cultivated cells) the Nanog gene 
was not expressed. 
 
  
Case Rep Oncol 2011;4:44–54 
DOI: 10.1159/000324403 
Published online: 
January 29, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
51
 
Fig. 3. Expression of Nanog protein in RPMI-cultivated cells. 
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Fig. 4. Expression of Nanog protein in STEMPRO-cultivated cells. 
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